Celcuity rises after FDA approval for breast cancer drug
CELC•FDA approves gedatolisib for advanced breast cancer
Biotech firm Celcuity's CELC.O shares rose 7.8% to $111.89 after the U.S. Food and Drug Administration approved CELC's gedatolisib with fulvestrant, with or without palbociclib, for advanced or metastatic breast cancer.
Gedatolisib is CELC's experimental breast cancer drug.
In June, CELC said gedatolisib extended the period of time a patient lives without the disease worsening.
CELC stock has risen nearly 8% year to date.
